RxDoctor Payments DataLook up a doctor →

Monika Ummat, MD

Clinical Neurophysiology · Houston, TXNPI 1184930018

Payments from drug & device makers

$54,687in general payments, 2019–2025

Across 766 payments — averaging $71.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$19K
  • Aquestive Therapeutics, Inc.$8K
  • Neurelis, Inc.$7K
  • Medtronic$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • UCB, Inc.$2K
  • plus $14K from 54 others
$5,673in research payments, 2019–2025

Across 7 payments — averaging $810.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K

What the payments were for

  • Consulting fees$1,3384%
  • Speaking & faculty fees$16,18546%
  • Travel & lodging$1,0343%
  • Food & beverage$16,91648%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly10$19,121
Aquestive Therapeutics, Inc.33$8,407
Neurelis, Inc.8$7,464
Medtronic(2 entities)41$2,021
Sunovion Pharmaceuticals Inc.20$1,864
UCB, Inc.62$1,582
AbbVie(2 entities)77$1,448
SK Life Science, Inc.51$1,349
Otter Pharmaceuticals, LLC1$1,338
Lundbeck LLC30$782
Jazz Pharmaceuticals Inc.21$685
Eisai Inc.27$614
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$573
Livanova USA, Inc.11$562
Supernus Pharmaceuticals, Inc.64$537
Merz North America, Inc.21$519
Teva Pharmaceuticals USA, Inc.19$424
Novartis23$410
Lilly USA, LLC13$399
Merz Pharmaceuticals, LLC16$388
Biogen12$364
Amgen14$362
Nevro Corp.6$283
Pfizer13$279
Takeda Pharmaceuticals U.S.A., Inc.10$264
Biohaven Pharmaceuticals, Inc.5$231
Grifols USA, LLC12$213
Axsome Therapeutics, Inc.4$191
GRT US Holding, Inc.13$184
Catalyst Pharmaceuticals, Inc.9$182
Arbor Pharmaceuticals, Inc.12$163
Collegium Pharmaceutical, Inc.9$128
Scilex Pharmaceuticals Inc.7$120
Argenx US, Inc.4$114
Boston Scientific5$111
Upsher-smith Laboratories LLC6$111
Tersera Therapeutics LLC2$75
Biohaven Pharmaceutical Holding Company Ltd.3$70
Azurity Pharmaceuticals, Inc.4$66
Amneal Pharmaceuticals LLC4$58
Averitas Pharma Inc.2$58
Johnson & Johnson(2 entities)3$57
Avanir Pharmaceuticals, Inc.3$50
Saluda Medical Americas, Inc.2$47
AstraZeneca3$47
Idorsia Pharmaceuticals US Inc3$43
SPR Therapeutics, Inc1$34
Biotronik NRO, Inc.1$31
Bausch Health US, LLC1$28
Biodelivery Sciences International, Inc.2$27
Redhill Biopharma Inc.2$25
Inspire Medical Systems, Inc.1$24
Elutia, Inc.1$22
Zyla Life Sciences, Inc.1$20
Life Molecular Imaging Ltd1$19
MDD US Operations, LLC1$18
Otsuka America Pharmaceutical, Inc.1$18
Almatica Pharma LLC1$16
Vertical Pharmaceuticals, LLC1$12
Abbott1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,687 in reported general payments places this provider in the 80th percentile of 50 clinical neurophysiology providers in Texas.

See all clinical neurophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$107,141
Medicare patients
103
Services billed
9,189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe16$11,820
ZtlidoLidocaine12$5,023
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$1,930
Fentanyl16$1,578
Gabapentin45$812
Pregabalin29$574
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$555
Duloxetine Hcl18$512
Methadone Hcl19$341
Tizanidine Hcl40$337
Tramadol Hcl29$236
Topiramate39$187
Donepezil Hcl14$157
Methocarbamol13$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$120$5,02312 claims
Upsher-smith Laboratories LLCTopiramate$111$18739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 clinical neurophysiology providers in Texas.

Other clinical neurophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →